1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Cylene Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Cylene Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 24 pages

Cylene Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Cylene Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Cylene Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cylene Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Cylene Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Cylene Pharmaceuticals, Inc. - Brief Cylene Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cylene Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cylene Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cylene Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Cylene Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cylene Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cylene Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cylene Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cylene Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Cylene Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Cylene Pharmaceuticals, Inc. Snapshot 4
Cylene Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Cylene Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Cylene Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Cylene Pharmaceuticals, Inc. - Pipeline Products Glance 9
Cylene Pharmaceuticals, Inc. Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Cylene Pharmaceuticals, Inc. - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Cylene Pharmaceuticals, Inc. - Drug Profiles 11
CX-5011 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
CX-5461 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
CX-8184 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
silmitasertib 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Cylene Pharmaceuticals, Inc. - Pipeline Analysis 15
Cylene Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 15
Cylene Pharmaceuticals, Inc. - Pipeline Products By Target 16
Cylene Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 17
Cylene Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 18
Cylene Pharmaceuticals, Inc. - Recent Pipeline Updates 19
Cylene Pharmaceuticals, Inc. - Dormant Projects 21
Cylene Pharmaceuticals, Inc. - Locations And Subsidiaries 22
Head Office 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24



List of Tables

Cylene Pharmaceuticals, Inc., Key Information 4
Cylene Pharmaceuticals, Inc., Key Facts 4
Cylene Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Cylene Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Cylene Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Cylene Pharmaceuticals, Inc. - Phase I, 2013 9
Cylene Pharmaceuticals, Inc. - Preclinical, 2013 10
Cylene Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 15
Cylene Pharmaceuticals, Inc. - Pipeline By Target, 2013 16
Cylene Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 17
Cylene Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 18
Cylene Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 19
Cylene Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 21



List of Figures

Cylene Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Cylene Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Cylene Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Cylene Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 18



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.